Finding 1056013 (2022-017)

Material Weakness Repeat Finding
Requirement
H
Questioned Costs
$1
Year
2022
Accepted
2024-07-29

AI Summary

  • Core Issue: The organization failed to show proper controls over the period of performance for six tested items, leading to questioned costs of $2,699.
  • Impacted Requirements: This issue relates to compliance with 2 CFR sections on budget periods, modifications, and closeout procedures.
  • Recommended Follow-Up: Management should strengthen controls to ensure documentation supports expenditures within the grant period to avoid future issues.

Finding Text

Formerly 2021-003: Period of Performance: Federal Program: Assistance Listing Nos.: 14.267 Continuum of Care Program Condition: The organization was unable to demonstrate controls over the period of performance for six items selected for testing. Criteria: The requirements for the period of performance are contained in 2 CFR section 200.1 Definitions for “budget period,” “financial obligations,” “period of performance,” 2 CFR section 200.308 (revision of budget and program plans), 2 CFR section 200.309 (modifications to period of performance), 2 CFR section 200.344 (closeout), program legislation, federal awarding agency regulations; and the terms and conditions of the award. Questioned Costs: There were six expenditures where no documentation could be provided to support that the expense was incurred during the grant period resulting in a questioned cost of $2,699 for 14.267. Cause: The Organization did not have good controls on ensuring the period of performance requirement was met due to staff turn over and being unable to locate documentation. Effect: The Organization could have grant expenditures outside the grant period. Recommendation: In order to prevent future occurrences of this deficiency, we recommend that management enhance a set of controls to ensure that they are able to demonstrate the period of performance. Perspective: This is a systemic issue in that controls over the requirement have not been developed to ensure the reported information is accurate. Repeat: This is a repeat finding. Responsible Official’s View: The Organization agrees with the finding. See attached corrective action plan.

Categories

Questioned Costs Period of Performance

Other Findings in this Audit

  • 479551 2022-013
    Material Weakness
  • 479552 2022-013
    Material Weakness
  • 479553 2022-014
    Material Weakness Repeat
  • 479554 2022-014
    Material Weakness Repeat
  • 479555 2022-014
    Material Weakness Repeat
  • 479556 2022-014
    Material Weakness Repeat
  • 479557 2022-014
    Material Weakness Repeat
  • 479558 2022-014
    Material Weakness Repeat
  • 479559 2022-014
    Material Weakness Repeat
  • 479560 2022-014
    Material Weakness Repeat
  • 479561 2022-014
    Material Weakness Repeat
  • 479562 2022-015
    Material Weakness Repeat
  • 479563 2022-015
    Material Weakness Repeat
  • 479564 2022-015
    Material Weakness Repeat
  • 479565 2022-015
    Material Weakness Repeat
  • 479566 2022-016
    Material Weakness Repeat
  • 479567 2022-016
    Material Weakness Repeat
  • 479568 2022-016
    Material Weakness Repeat
  • 479569 2022-016
    Material Weakness Repeat
  • 479570 2022-017
    Material Weakness Repeat
  • 479571 2022-017
    Material Weakness Repeat
  • 479572 2022-017
    Material Weakness Repeat
  • 479573 2022-017
    Material Weakness Repeat
  • 479574 2022-018
    Material Weakness Repeat
  • 479575 2022-018
    Material Weakness Repeat
  • 479576 2022-018
    Material Weakness Repeat
  • 479577 2022-018
    Material Weakness Repeat
  • 479578 2022-018
    Material Weakness Repeat
  • 479579 2022-018
    Material Weakness Repeat
  • 1055993 2022-013
    Material Weakness
  • 1055994 2022-013
    Material Weakness
  • 1055995 2022-014
    Material Weakness Repeat
  • 1055996 2022-014
    Material Weakness Repeat
  • 1055997 2022-014
    Material Weakness Repeat
  • 1055998 2022-014
    Material Weakness Repeat
  • 1055999 2022-014
    Material Weakness Repeat
  • 1056000 2022-014
    Material Weakness Repeat
  • 1056001 2022-014
    Material Weakness Repeat
  • 1056002 2022-014
    Material Weakness Repeat
  • 1056003 2022-014
    Material Weakness Repeat
  • 1056004 2022-015
    Material Weakness Repeat
  • 1056005 2022-015
    Material Weakness Repeat
  • 1056006 2022-015
    Material Weakness Repeat
  • 1056007 2022-015
    Material Weakness Repeat
  • 1056008 2022-016
    Material Weakness Repeat
  • 1056009 2022-016
    Material Weakness Repeat
  • 1056010 2022-016
    Material Weakness Repeat
  • 1056011 2022-016
    Material Weakness Repeat
  • 1056012 2022-017
    Material Weakness Repeat
  • 1056014 2022-017
    Material Weakness Repeat
  • 1056015 2022-017
    Material Weakness Repeat
  • 1056016 2022-018
    Material Weakness Repeat
  • 1056017 2022-018
    Material Weakness Repeat
  • 1056018 2022-018
    Material Weakness Repeat
  • 1056019 2022-018
    Material Weakness Repeat
  • 1056020 2022-018
    Material Weakness Repeat
  • 1056021 2022-018
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
16.576 Crime Victim Compensation $273,735
93.788 Opioid Str $85,216
14.267 Continuum of Care Program $60,141
93.558 Temporary Assistance for Needy Families $47,833
16.588 Violence Against Women Formula Grants $36,160
94.006 Americorps $23,030
10.558 Child and Adult Care Food Program $20,513